Abstract Details

Title Food Allergies Are Associated With Increased Disease Activity In Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-068

Objective

To assess the association between a self-reported history of allergic conditions and multiple sclerosis (MS) clinical and MRI disease activity.

Background Epidemiological studies investigating the association between a history of allergy and the risk of MS have shown conflicting results. Despite this controversy, one relevant question remains unanswered: is MS activity less or more intense among patients with an atopic history?

Design/Methods A subset of 1,349 patients enrolled in the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women’s Hospital (CLIMB) study completed a self-administered questionnaire on environmental, food and drug allergies. Patients were distributed among four allergy groups: 1-environmental, 2-food, 3-drug, and 4-no known allergies (NKA). Clinical (number of attacks, expanded disability status scale [EDSS], MS severity score [MSSS]) and radiological variables (presence of Gadolinium (Gad)-enhancing lesions and lesion count) were analyzed between the different allergy groups with NKA.

Results

The mean follow-up period between the questionnaire date and the analysis visit date was 2.0 (1.8)
years for the whole cohort. The food allergy group had a rate 1.38 times higher for cumulative number of attacks compared to the NKA group (p=0.0062); this difference remained significant in the adjusted analysis (relapse rate ratio 1.27, p=0.0305). The food allergy group showed more than twice the likelihood (OR=2.53, p-value=0.0096) to have a Gad-enhancing lesion. The environmental and drug allergy groups did not show major differences when compared to the NKA group. The EDSS and MSSS were not affected by any type of allergy.

Conclusions

MS patients with food allergy had more relapses and a higher likelihood of Gad-enhancing lesions as compared to patients with no known allergy. Future prospective studies are needed to confirm our findings and understand the underlying biological mechanism, which can lead to new therapeutic and preventative strategies for MS.

Authors/Disclosures
Rami Fakih, MD (University of Missouri) PRESENTER	Dr. Fakih has nothing to disclose.
Camilo Diaz-Cruz, MD	Dr. Diaz-Cruz has nothing to disclose.
	No disclosure on file
Cindy Gonzalez (Brigham and Women'S Hospital)	No disclosure on file
Brian C. Healy	The institution of Mr. Healy has received research support from Analysis Group. The institution of Mr. Healy has received research support from Bristol-Myers Squibb. The institution of Mr. Healy has received research support from Verily Life Sciences. The institution of Mr. Healy has received research support from Novartis. The institution of Mr. Healy has received research support from Merck Serono. The institution of Mr. Healy has received research support from Genzyme.
Neda Sattarnezhad Oskouei, MD (Stanford Univesrity)	Dr. Sattarnezhad Oskouei has received research support from National Institutes of Health (NIH). Dr. Sattarnezhad Oskouei has received research support from National Institute of Allergy and Infectious Diseases (NIAID).
Bonnie Glanz (Brigham and Women'S Hospital)	The institution of Ms. Glanz has received research support from CMSC. The institution of Ms. Glanz has received research support from NIH.
Howard L. Weiner, MD (Brigham and Women'S Hospital)	Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital)	Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.

��ɫ��

��ɫ��